跳至主要内容

MedPath Trial Home

机构资讯 AI 研究

数据来源：ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

搜索试验。追踪管线。洞察审批。由 AI 驱动的临床研究情报平台。

产品

临床试验
药物情报
全球审批
深度研究
价格方案

资源

常见问题
搜索

公司

资讯
关于我们
联系我们

法律

隐私政策
服务条款

免责声明： 本网站提供信息检索和数据分析服务。内容不构成医疗建议。适应性评估仅供参考，不能替代合格医疗专业人员的咨询。数据来源于公共注册库和监管机构；MedPath 不保证数据的完整性或准确性。请以原始资料为准。

© 2026 MedPath Trial 版权所有

服务条款隐私政策

我们重视您的隐私

我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。

Telix International Pty Ltd

首页临床试验发起方与机构Telix International Pty Ltd

Telix International Pty Ltd

ACTIVE

Private

隶属于 Telix Pharmaceuticals Ltd.

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

相关临床试验

8

6 进行中

药物批准

0

批准总数

监管机构

0

监管机构数

成立时间

N/A

概览

试验阶段分布

阶段

试验数

占比

1 期

6

75.0%

2 期

1

12.5%

试验状态分布

进行中（未招募）

6

75.0%

已完成

2

25.0%

相关临床试验

该机构主办的试验（8）

Safety, distribution and metabolism of 89Zr-DFO-girentuximab in bodies of patients with masses of unknown nature on their kidneys.

进行中（未招募）

May 202310 名受试者

89Zirconium-labelled girentuximab (89Zr-TLX250) is a new diagnostic imaging agent which has a radionuclide (zirconium-89) linked with a drug known as girentuximab. The drug is known to be taken up by clear cell renal cell carcinoma. This product would be administered and then a scan of the body made by a PET/CT machine. This study is to determine the ability of the administered zirconium-89 girentuximab to correctly identify the nature of the known or suspected cancer within your kidney.

进行中（未招募）

Aug 2019300 名受试者

89Zirconium-labelled girentuximab (89Zr-TLX250) is a new diagnostic imaging agent which has a radionuclide (zirconium-89) linked with a drug known as girentuximab. The drug is known to be taken up by clear cell renal cell carcinoma. This product would be administered and then a scan of the body made by a PET/CT machine. This study is to determine the ability of the administered zirconium-89 girentuximab to correctly identify the nature of the known or suspected cancer within your kidney.

进行中（未招募）

Jun 2019252 名受试者

A clinical trial that is optimising 2 radioactive anti-cancer treatments to see if the combination is safe and effective for patients with a form of brain cancer known as GBM.

进行中（未招募）

Mar 201944 名受试者

89Zirconium-labelled girentuximab (89Zr-TLX250) is a new diagnostic imaging agent which has a radionuclide (zirconium-89) linked with a drug known as girentuximab. The drug is known to be taken up by clear cell renal cell carcinoma. This product would be administered and then a scan of the body made by a PET/CT machine. This study is to determine the ability of the administered zirconium-89 girentuximab to correctly identify the nature of the known or suspected cancer within your kidney.

进行中（未招募）

Nov 2018252 名受试者

A clinical trial that is optimising 2 radioactive anti-cancer treatments to see if the combination is safe and effective for patients with a form of brain cancer known as GBM.

进行中（未招募）

Jul 201844 名受试者

An open-label, Phase I study to assess safety, tolerability, radiation dosimetry, and imaging properties of 89Zr-labelled girentuximab (89Zr-girentuximab) for in vivo detection of clear cell renal carcinoma (CCRC) by positron emission tomography (PET) using different PET imaging methodologies.

10 名受试者

A multi-centre, open-label, single-arm, dose-finding phase I/II study to evaluate safety, tolerability, dosing schedule, and preliminary efficacy of carrier-added 4-L-[131I]iodo-phenylalanine (131I-IPA), administered as single or repetitive injections in patients with recurrent glioblastoma multiforme (GBM), concomitantly to 2nd line external radiation therapy (XRT) - IPAX-1Study

药物批准

暂无批准数据

资讯

暂无资讯文章

本页目录

概览
相关临床试验8
药物批准
资讯

返回机构列表